Complement C3 Test

Your standard blood work checks cholesterol, blood sugar, and a handful of organ markers. None of them tell you whether your immune system's most ancient defense network is running hot, silently fueling the inflammation that drives diabetes, blood clots, and blood vessel damage. Complement C3 (the third component of the complement system, a cascade of proteins that form the immune system's first line of defense) fills that gap.

In a study of over 95,000 adults from the general population, people with the highest C3 levels had roughly triple the risk of diabetic eye damage and nearly triple the risk of diabetic kidney damage compared to those with the lowest levels. That kind of predictive power, reaching across multiple organ systems at once, makes C3 one of the more informative single markers for metabolic and vascular risk that most people have never heard of.

What C3 Does in Your Body

C3 is a large protein produced mainly by the liver, though fat cells, immune cells, and tissues throughout the body also make it. It sits at the convergence point of three different immune activation routes (called the classical, lectin, and alternative pathways). When any of these pathways detects a threat, they cut C3 into two fragments: C3a, which triggers inflammation, and C3b, which tags invaders for destruction and amplifies the immune response.

But C3 does more than fight infection. One of its breakdown products, called acylation-stimulating protein, directly promotes fat storage and glucose uptake in fat tissue. This means C3 is not just an immune marker. It is woven into the biology of obesity, insulin resistance, and fatty liver disease. When your body carries excess visceral fat, those fat cells pump out extra C3, creating a feedback loop between immune activation and metabolic dysfunction.

Type 2 Diabetes Risk

The link between C3 and diabetes is one of the strongest and most consistent findings in the research. In a cohort of about 2,800 Swedish men followed for six years, those in the top quarter of C3 levels were roughly 5.6 times more likely to develop type 2 diabetes than those in the bottom quarter, after adjusting for age, baseline blood sugar, BMI, insulin levels, and other inflammatory markers. C3 was the only inflammatory protein that remained significant after all adjustments.

A separate 10-year study of about 2,700 middle-aged and older adults found that each standard-deviation increase in C3 raised diabetes risk by about 16%, and people in the highest quarter had about 52% higher risk than those in the lowest quarter. Roughly 41% of this association was explained by BMI, meaning that obesity accounts for a large share of the link, but not all of it. C3 appears to contribute to diabetes risk through pathways that go beyond body weight alone.

If your C3 is in the upper range and you already have borderline blood sugar or a family history of diabetes, this combination deserves attention. Tracking C3 alongside fasting insulin and HbA1c (a measure of average blood sugar over three months) gives you a broader picture of metabolic risk than glucose-based tests alone.

Diabetic Eye, Kidney, and Nerve Damage

Beyond predicting diabetes itself, C3 also forecasts the complications that make diabetes dangerous. In a study of over 95,000 adults from the Copenhagen General Population Study, each standard-deviation rise in C3 was associated with about 87% higher risk of diabetic retinopathy (damage to the blood vessels of the eye), 90% higher risk of diabetic nephropathy (kidney damage), and 56% higher risk of diabetic neuropathy (nerve damage).

Comparing the highest third of C3 to the lowest third, the risks were roughly 3.3 times higher for retinopathy, 2.7 times higher for nephropathy, and 2.4 times higher for neuropathy. An analysis using genetic variants associated with higher C3 (a technique called Mendelian randomization, which tests whether a biomarker is likely to be a cause rather than just a bystander) supported a causal role for C3 in microvascular disease.

For anyone already living with diabetes or prediabetes, a high C3 reading adds urgency to blood sugar management, blood pressure control, and eye and kidney screening.

Blood Clot Risk

Complement C3 also predicts the risk of venous thromboembolism, or VTE (blood clots in the deep veins or lungs). In over 80,000 adults from the Copenhagen General Population Study followed for up to a decade, people in the middle third of C3 had about 36% higher VTE risk than those in the bottom third, and people in the top third had about 58% higher risk. For each 1 g/L increase in C3 (equivalent to 100 mg/dL), the risk roughly 2.4 times higher.

These associations held after adjusting for age, sex, and conventional VTE risk factors, and were only modestly weakened after further adjustment for CRP (high-sensitivity C-reactive protein, a general inflammation marker) and BMI. This suggests that C3 captures a dimension of clotting risk that standard inflammation markers do not fully explain.

Heart Disease and Stroke

In a study of about 760 middle-aged adults undergoing coronary angiography, C3 was independently associated with the presence of coronary artery disease after adjusting for standard risk factors. C3 outperformed CRP as an indicator of coronary disease in that population.

After a stroke, C3 carries prognostic weight. Among over 3,400 patients hospitalized for ischemic stroke across 26 hospitals, those in the highest third of C3 at admission had about 30% higher odds of death or major disability at three months compared to the lowest third. Each standard-deviation increase in C3 raised the odds of a poor outcome by about 13%, and adding C3 to conventional risk models improved prediction by roughly 9%.

Fatty Liver Disease

In a cross-sectional study of about 3,700 Chinese adults undergoing routine health checks, each standard-deviation rise in C3 increased the odds of metabolic-associated fatty liver disease (MAFLD) by about 33%. Obesity partly explained this relationship, consistent with the fact that fat cells are a significant source of C3. For people concerned about liver health, C3 adds context to liver enzyme tests like ALT (alanine aminotransferase), which measures liver cell damage but does not capture the inflammatory and immune activation that drives fatty liver progression.

Asthma Hospitalizations

In over 101,000 adults from the Copenhagen General Population Study, people in the highest third of C3 had about 23% higher risk of being hospitalized for asthma compared to the lowest third. Among a subgroup of about 2,200 adults with allergic asthma, the highest C3 third had a 69% higher rate of asthma exacerbations. Genetic analyses supported a causal link, though the authors noted results may not generalize beyond people of Danish descent.

When Low C3 Signals Trouble

Everything above describes the risks of high C3. But low C3 tells a different story, and understanding this distinction is essential. When C3 drops below normal, it usually means the complement system is being consumed faster than the liver can replace it. This happens during intense immune activation, particularly in autoimmune diseases like lupus and ANCA-associated vasculitis (a condition where immune proteins attack small blood vessels), and in a severe inflammatory condition called HLH (hemophagocytic lymphohistiocytosis, a life-threatening immune overactivation syndrome).

In a large cohort of over 1,200 adults with HLH, low C3 predicted progression from partial to full HLH (with roughly 4 times the odds), correlated with organ dysfunction, and independently predicted early death. Patients who survived showed rising C3 as treatment took hold, while those who died showed continued decline.

In ANCA-associated vasculitis, low C3 at diagnosis has been linked to more kidney damage, higher rates of dialysis, greater relapse risk, and shorter survival.

Making Sense of the Two Directions

C3 is not a simple "higher is worse" or "lower is better" marker. Think of it as a gauge of immune and metabolic pressure. High C3 reflects chronic, low-grade activation driven by fat tissue, metabolic stress, and vascular inflammation. It signals that your body is slowly fueling the processes behind diabetes, blood clots, and artery damage. Low C3, on the other hand, reflects acute, high-intensity immune consumption, where the complement system is being used up faster than it can be rebuilt, often in the context of autoimmune disease or severe inflammatory crises.

Your clinical context determines which direction matters more. If you are tracking metabolic and cardiovascular risk as a generally healthy person, a reading in the upper range is the signal to pay attention to. If you have a known autoimmune condition, a drop below normal is the concerning finding.

Reference Ranges

Most clinical laboratories report a normal range for C3 of approximately 90 to 180 mg/dL, though exact cutpoints vary by lab and assay method. These ranges are designed to flag clearly abnormal values (very low in complement consumption, very high in acute inflammation), not to identify the metabolic risk gradients that large population studies have uncovered.

The research-based risk tiers below come from large European cohort studies using nephelometric assays. They are converted here from g/L to mg/dL for consistency with most U.S. lab reports. Because different labs use different instruments and calibrators, treat these as orientation rather than fixed targets. Always compare your results within the same lab over time.

A reading below 90 mg/dL in someone without a known autoimmune condition warrants investigation for complement consumption, liver dysfunction, or a rare complement deficiency.

When Results Can Be Misleading

C3 behaves as a chronic, slow-moving marker with low biological variability (within-person variation of roughly 5 to 7% in healthy adults). That stability is an advantage for trending, but a few factors can shift the number in ways that do not reflect your true baseline.

• Acute illness or surgery: Any significant infection, tissue injury, or surgical procedure can raise complement activation acutely. If you have been sick or had a procedure in the past two to three weeks, your C3 may be temporarily elevated or, in severe cases, depleted. Wait until you are fully recovered before drawing conclusions from a single reading.
• Recent weight change: Because fat tissue produces C3, rapid weight gain or loss can shift your level independently of any change in immune or vascular health. A C3 result obtained during active weight loss may be transiently lower than your long-term baseline.
• Obesity and metabolic syndrome: C3 is strongly confounded by BMI, waist circumference, insulin resistance, and liver fat. Roughly 40 to 55% of the association between C3 and metabolic disease is explained by obesity. If your BMI is above 30, an elevated C3 reading likely reflects metabolic inflammation from excess fat tissue rather than a separate immune problem.
• Liver disease: Since the liver is the primary source of C3, severe liver dysfunction can lower C3 through reduced production, while early fatty liver disease may raise it through inflammatory signaling. Interpret C3 alongside liver function tests like ALT and GGT (gamma-glutamyl transferase, an enzyme that signals liver stress).

Tracking Your Trend

Because C3 has relatively low within-person variability (about 5 to 7%), your personal trend is more meaningful than any single reading compared to a population reference range. A change of roughly 15 to 20% between two tests drawn at the same lab, under similar conditions, is more likely to reflect a genuine biological shift than measurement noise.

Get a baseline, then retest in three to six months if you are making lifestyle changes (especially weight loss, which has the strongest evidence for lowering C3). After that, annual monitoring is reasonable for anyone tracking metabolic and cardiovascular health. If you have an autoimmune condition, your specialist will likely want more frequent monitoring during flares or treatment changes.

Serial tracking is particularly valuable because C3 sits at the intersection of immune and metabolic biology. Watching your C3 move alongside HbA1c, fasting insulin, and hs-CRP gives you a multidimensional view of whether your interventions are working across both systems simultaneously.

What to Do With Your Results

If your C3 is in the upper range (above about 120 mg/dL) and you are otherwise healthy, the most productive next steps are to check your metabolic markers: fasting insulin, HbA1c, triglycerides, and liver enzymes. If those are also trending unfavorably, the pattern points to metabolic inflammation, and the most effective response is reducing visceral fat through dietary changes and exercise. A repeat C3 in three to six months after sustained weight loss can confirm whether the immune-metabolic signal is improving.

If your C3 is below 90 mg/dL without a known explanation, order Complement C4 alongside it. Low C3 with normal C4 suggests alternative pathway consumption (seen in conditions like C3 glomerulopathy). Low C3 and low C4 together point toward classical pathway activation, which is common in lupus and immune-complex diseases. Either pattern warrants evaluation by a rheumatologist or nephrologist depending on your symptoms. An ANA (antinuclear antibody) screen is a reasonable companion test if autoimmune disease is suspected.

If your C3 is within a normal range but you are tracking it for metabolic risk, pair it with hs-CRP. These two markers capture different facets of inflammation: CRP reflects general systemic inflammation driven largely by the liver's response to cytokines, while C3 reflects complement-specific activation and metabolic signaling from fat tissue. When both are elevated, the metabolic inflammatory burden is more convincing than when either is elevated alone.